Vicore Pharma Holding Logo

Vicore Pharma Holding

ISIN: SE0007577895 | Ticker: VICO | LEI: 549300KTNBPTZLF01130
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Sweden

About Vicore Pharma Holding

Company Description

We are an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments for severe lung diseases. Embedded in our approach is the determination to find solutions for conditions which have an enormous deleterious impact on patients and their families and to transform the lives of those affected.

Patients with severe lung diseases can suffer from progressive difficulty in breathing and a relentless deterioration in quality of life. Receiving such a diagnosis can be devastating, due to the poor prognosis. We appreciate that living with such diseases presents a constant challenge, not only for patients but also for their families and caregivers. Our research and drug development programmes are specifically aimed at alleviating these challenges with the patient at the forefront of our minds.

Year founded


Served area



Kronhusgatan 11, 41105 Göteborg – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2021 01.01.2022 01.01.2023
Assets N/A 451,168,000.00 338,007,000.00
Noncurrent Assets N/A 73,237,000.00 68,217,000.00
Property Plant And Equipment N/A 84,000.00 54,000.00
Copyrights Patents And Other Industrial Property Rights Service And Operating Rights N/A 67,427,000.00 68,100,000.00
Noncurrent Investments Other Than Investments Accounted For Using Equity Method N/A 5,409,000.00 0.00
Current Assets N/A 377,931,000.00 269,790,000.00
Other Current Receivables N/A 1,417,000.00 2,180,000.00
Cash and cash equivalents 248,618,000.00 294,199,000.00 256,803,000.00
Current Investments N/A 77,281,000.00 4,940,000.00
Equity And Liabilities N/A 451,168,000.00 338,007,000.00
Equity 354,513,000.00 383,316,000.00 289,083,000.00
Issued Capital N/A 35,880,000.00 40,924,000.00
Retained Earnings N/A -674,230,000.00 -962,652,000.00
Additional Paidin Capital N/A 1,021,666,000.00 1,210,811,000.00
Liabilities N/A 67,852,000.00 48,924,000.00
Noncurrent Liabilities N/A 2,130,000.00 2,505,000.00
Other Longterm Provisions N/A 600,000.00 1,600,000.00
Deferred Tax Liabilities N/A 1,210,000.00 905,000.00
Current Liabilities N/A 65,722,000.00 46,419,000.00
Other Shortterm Provisions N/A 152,000.00 127,000.00
Trade And Other Current Payables To Trade Suppliers N/A 23,984,000.00 23,495,000.00
Current Accruals And Current Deferred Income Including Current Contract Liabilities N/A 40,139,000.00 18,221,000.00
Current Tax Liabilities Current N/A 335,000.00 760,000.00
Other Current Liabilities N/A 1,112,000.00 3,751,000.00
Line item in (sek) 01.01.2021/
Revenue 0.00 0.00
Profit Loss From Operating Activities -294,818,000.00 -290,725,000.00
Finance Income 646,000.00 2,395,000.00
Finance Costs 2,563,000.00 476,000.00
Profit Loss Before Tax -296,735,000.00 -288,806,000.00
Income Tax Expense Continuing Operations -254,000.00 -384,000.00
Profit (loss) -296,481,000.00 -288,422,000.00
Profit Loss Attributable To Owners Of Parent -296,481,000.00 -288,422,000.00
Line item in (sek) 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -296,481,000.00 -288,422,000.00
Interest Paid Classified As Operating Activities N/A 8,000.00 8,000.00
Interest Received Classified As Operating Activities N/A 483,000.00 1,194,000.00
Cash Flows From Used In Operating Activities N/A -265,171,000.00 -299,919,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 0.00 3,000,000.00
Cash Flows From Used In Investing Activities N/A -7,000,000.00 74,000,000.00
Proceeds From Issuing Shares N/A 336,000,000.00 200,000,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 239,000.00 252,000.00
Cash Flows From Used In Financing Activities N/A 318,183,000.00 187,040,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 46,012,000.00 -38,879,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -431,000.00 1,483,000.00
Cash and cash equivalents 248,618,000.00 294,199,000.00 256,803,000.00

Please note that some sums might not add up.

Filings & Publications


Consolidated Report
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
08.06.22 Jacob Uno Stanley Gunterberg Other Buy SEK 220,800.00
03.06.22 Johannes Schikan Other Buy SEK 119,880.00
03.06.22 Sara Malcus Other Buy SEK 87,495.30
01.06.22 Maarten Kraan Other Buy SEK 121,152.50
16.09.21 Carl Johan Dalsgaard Other Other SEK 0.00
06.10.20 Carl Johan Dalsgaard Other Other SEK 0.00
04.06.20 Heidi Hunter Other Buy SEK 0.00

Capital markets information






Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences





Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.